Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression

Journal of Neuropathology and Experimental Neurology

Volumn 68, Issue 10, 2009, Pages 1073-1083

  Song, Yun Ju C ^a   Halliday, Glenda M ^a,f   Holton, Janice L ^b   Lashley, Tammaryn ^b   Osullivan, Seán S ^b   McCann, Heather ^a   Lees, Andrew J ^b   Ozawa, Tetsutaro ^b,c   Williams, David R ^b,d   Lockhart, Paul J ^e   Revesz, Tamas R ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Niigata University   (Japan)

^d MONASH UNIVERSITY   (Australia)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

^f NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

Synuclein; Astrocytes; Corticobasal degeneration; Multiple system atrophy; Parkin, Parkinson disease; Progressive supranuclear palsy; Tau.

Indexed keywords

ALPHA SYNUCLEIN; APOLIPOPROTEIN D; PARKIN;

ARTICLE; ASTROCYTE; CELL TYPE; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DISEASE COURSE; DISEASE SEVERITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NERVE DEGENERATION; NEUROPATHOLOGY; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN EXPRESSION; SHY DRAGER SYNDROME; TISSUE DISTRIBUTION;

ALPHA-SYNUCLEIN; APOLIPOPROTEINS D; ASTROCYTES; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE TRANSPORT PROTEINS; MULTIPLE SYSTEM ATROPHY; NERVE DEGENERATION; PARKINSON DISEASE; PARKINSONIAN DISORDERS; PHOSPHORYLATION; PONS; PUTAMEN; SEVERITY OF ILLNESS INDEX; SUBSTANTIA NIGRA; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS;

EID: 70349736190     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3181b66f1b     Document Type: Article

References (62)

1. Hirsch EC, Hunot S, Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat Disord 2005;11:S9YS15
2. Mirza B, Hadberg H, Thomsen P, et al. The absence of reactive astro-cytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 2000;95:425-32
3. Vila M, Jackson-Lewis V, Guegan C, et al. The role of glial cells in Parkinson's disease. Curr Opin Neurol 2001;14:483-89
4. Braak H, Sastre M, Del Tredici K. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intra-neuronal pathology in sporadic Parkinson's disease. Acta Neuropathol 2007;114:231-41
5. Wakabayashi K, Hayashi S, Yoshimoto M, et al. NACP/alpha-synucleinY positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol 2000;99:14-20
6. Ozawa T, Paviour D, Quinn NP, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: Clinicopathological correlations. Brain 2004; 127:2657-71
7. Togo T, Dickson DW. Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process. Acta Neuropathol 2002;104:398-402
8. Wakabayashi K, Takahashi H. Pathological heterogeneity in progressive supranuclear palsy and corticobasal degeneration. Neuropathology 2004; 24:79-86
9. Korzhevskii DE, Otellin VA, Grigor'ev IP. Glial fibrillary acidic protein in astrocytes in the human neocortex. Neurosci Behav Physiol 2005;35: 789-92
10. Navarro A, Del Valle E, Tolivia J. Differential expression of apoli-poprotein d in human astroglial and oligodendroglial cells. J Histochem Cytochem 2004;52:1031-36
11. Ledesma MD, Galvan C, Hellias B, et al. Astrocytic but not neuronal increased expression and redistribution of parkin during unfolded protein stress. J Neurochem 2002;83:1431-40
12. Taylor JM, Song YJ, Huang Y, et al. Parkin Co-Regulated Gene (PACRG) is regulated by the ubiquitin-proteasomal system and is present in the pathological features of Parkinsonian diseases. Neurobiol Dis 2007;27:238-47
13. Bandopadhyay R, Kingsbury AE, Cookson MR, et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 2004;127:420-30
14. Gandhi S, Muqit MM, Stanyer L, et al. PINK1 protein in normal human brain and Parkinson's disease. Brain 2006;129:1720-31
15. West AB, Lockhart PJ, O'Farell C, et al. Identification of a novel gene linked to parkin via a bi-directional promoter. J Mol Biol 2003;326: 11-19
16. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39
17. Trojanowski JQ, Revesz T. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 2007;33:615-20
18. Wenning GK, Colosimo C, Geser F, et al. Multiple system atrophy. Lancet Neurol 2004;3:93-103
19. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9
20. Dickson DW, Bergeron C, Chin SS, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002;61:935-46
21. Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supra-nuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005;128:1247-58
22. Williams DR, Holton JL, Strand C, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain 2007;130:1566-76
23. Lockhart PJ, O'Farrell CA, Farrer MJ. It's a double knock-out! The quaking mouse is a spontaneous deletion of parkin and parkin co-regulated gene (PACRG). Mov Disord 2004;19:101-4
24. Song YJ, Lundvig DM, Huang Y, et al. p25alpha relocalizes in oligo-dendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol 2007;171:1291-303
25. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211
26. Jellinger KA, Seppi K, Wenning GK. Grading of neuropathology in multiple system atrophy: Proposal for a novel scale. Mov Disord 2005; 20:S29-S36
27. Broe M, Hodges JR, Schofield E, et al. Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology 2003;60:1005-11
28. Komori T. Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease. Brain Pathol 1999;9: 663-79
29. Zarate-Lagunes M, Gu WJ, Blanchard V, et al. Parkin immunoreactivity in the brain of human and non-human primates: An immunohistochem-ical analysis in normal conditions and in Parkinsonian syndromes. J Comp Neurol 2001;432:184-96
30. Tan AM, Zhang W, Levine JM. NG2: A component of the glial scar that inhibits axon growth. J Anat 2005;207:717-25
31. Nishiyama A, Yang Z, Butt A. Astrocytes and NG2-glia: What's in a name? J Anat 2005;207:687-93
32. Bushong EA, Martone ME, Jones YZ, et al. Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. J Neurosci 2002;22:183-92
33. Snyder SH, Kim PM. D-Amino acids as putative neurotransmitters: Focus on D-serine. Neurochem Res 2000;25:553-60
34. Ikeda K, Ikeda T, Morikawa K, et al. Axonemal localization of Chlamydomonas PACRG, a homologue of the human Parkin-coregulated gene product. Cell Motil Cytoskeleton 2007;64:814-21
35. Ikeda T. Parkin-co-regulated gene (PACRG) product interacts with tubulin and microtubules. FEBS Lett 2008;582:1413-18
36. Ito K, Arai K, Yoshiyama Y, et al. Astrocytic tau pathology positively correlates with neurofibrillary tangle density in progressive supranuclear palsy. Acta Neuropathol 2008;115:623-28
37. Schofield E, Kersaitis C, Shepherd CE, et al. Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: Tau-positive glia differentiate these disorders. Brain 2003;126:827-40
38. Brody KM, Taylor JM, Wilson GR, et al. Regional and cellular localisation of Parkin co-regulated gene in developing and adult mouse brain. Brain Res 2008;1201:177-86
39. Yang F, Jiang Q, Zhao J, et al. Parkin stabilizes microtubules through strong binding mediated by three independent domains. J Biol Chem 2005;280:17154-62
40. D'Agata V, Grimaldi M, Pascale A, et al. Regional and cellular expression of the parkin gene in the rat cerebral cortex. Eur J Neurosci 2000;12:3583-88
41. Houlden H, Baker M, Morris HR, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001;56:1702-6
42. Broe M, Kril J, Halliday GM. Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. Brain 2004;127:2214-20
43. Klein RL, Dayton RD, Henderson KM, et al. Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegenera-tion model. Neurosci Lett 2006;401:130-35
44. Menendez J, Rodriguez-Navarro JA, Solano RM, et al. Suppression of Parkin enhances nigrostriatal and motor neuron lesion in mice over-expressing human-mutated tau protein. Hum Mol Genet 2006;15:2045-58
45. Navarro P, Guerrero R, Gallego E, et al. Memory and exploratory impairment in mice that lack the Park-2 gene and that over-express the human FTDP-17 mutant Tau. Behav Brain Res 2008;189:350-56
46. Rodriguez-Navarro JA, Casarejos MJ, Menendez J, et al. Mortality, oxidative stress and tau accumulation during ageing in parkin null mice. J Neurochem 2007;103:98-114
47. Ros R, Ampuero I, Garcia de Yebenes J. Parkin polymorphisms in progressive supranuclear palsy. J Neurol Sci 2008;268:176-78
48. Solano RM, Casarejos MJ, Menendez-Cuervo J, et al. Glial dysfunction in parkin null mice: Effects of aging. J Neurosci 2008;28:598-611
49. Schlehe JS, Lutz AK, Pilsl A, et al. Aberrant folding of pathogenic Parkin mutants: Aggregation versus degradation. J Biol Chem 2008;283: 13771-79
50. Arima K. Ultrastructural characteristics of tau filaments in tauopathies: Immuno-electron microscopic demonstration of tau filaments in tauo-pathies. Neuropathology 2006;26:475-83
51. Yamada T, McGeer PL, McGeer EG. Appearance of paired nucleated, Tau-positive glia in patients with progressive supranuclear palsy brain tissue. Neurosci Lett 1992;135:99-102
52. Santpere G, Ferrer I. Delineation of early changes in cases with progressive supranuclear palsyYlike pathology. Astrocytes in striatum are primary targets of tau phosphorylation and GFAP oxidation. Brain Pathol 2009;19:177-87
53. Mori F, Tanji K, Zhang H, et al. alpha-Synuclein pathology in the neostriatum in Parkinson's disease. Acta Neuropathol 2008;115:453-59
54. Tanji K, Mori F, Nakajo S, et al. Expression of beta-synuclein in normal human astrocytes. Neuroreport 2001;12:2845-48
55. Tanji K, Imaizumi T, Yoshida H, et al. Expression of alpha-synuclein in a human glioma cell line and its up-regulation by interleukin-1beta. Neuroreport 2001;12:1909-12
56. Stefanova N, Emgard M, Klimaschewski L, et al. Ultrastructure of alpha-synucleinYpositive aggregations in U373 astrocytoma and rat primary glial cells. Neurosci Lett 2002;323:37-40
57. Stefanova N, Schanda K, Klimaschewski L, et al. Tumor necrosis factorYalphaYinduced cell death in U373 cells overexpressing alpha-synuclein. J Neurosci Res 2003;73:334-40
58. Stefanova N, Klimaschewski L, Poewe W, et al. Glial cell death induced by overexpression of alpha-synuclein. J Neurosci Res 2001;65:432-38
59. Sasaki S, Shirata A, Yamane K, et al. Parkin-positive autosomal recessive juvenile Parkinsonism with alpha-synucleinYpositive inclusions. Neurology 2004;63:678-82
60. Schiesling C, Kieper N, Seidel K, et al. Review: Familial Parkinson's diseaseVGenetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathol Appl Neurobiol 2008;34:255-71
61. van de Warrenburg BP, Lammens M, Lucking CB, et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001;56:555-57
62. Ishizawa K, Komori T, Arai N, et al. Glial cytoplasmic inclusions and tissue injury in multiple system atrophy: A quantitative study in white matter (olivopontocerebellar system) and gray matter (nigrostriatal system). Neuropathology 2008;28:249-57